Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Special Report 2 Small-Cap Biotechs That Could Reward Patient InvestorsAuthor: Chris Markoch. First Published: 12/12/2025. 
Quick Look - Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculative investors and patience rarely go together. Nevertheless, if you're looking to invest in the small-cap biotech sector, patience is essential. Most of these companies are still in the clinical stage and have no commercially available drugs or therapeutics. That also means they generally have negative earnings (are not profitable) and little to no revenue. Success often hinges on the outcome of a single clinical-stage drug or therapeutic. If you've built substantial wealth, capital gains taxes may quietly erode far more of your investment returns than you realize.
The good news? The tax code offers legitimate ways to potentially help minimize that bill - if you know where to look.
Here are three high-impact areas where strategic planning may help minimize your capital gains tax. Try SmartAsset's Financial Advisor Matching Tool Even if a product advances through trials, profitability can still be years away. Only after hitting that milestone do companies typically gain the analyst coverage that attracts institutional investment. Still, getting in on one of these medical stocks and seeing it succeed can feel like winning the lottery — investors can sometimes see 3x, 5x, or even 10x returns. Many others never pan out, which is why some investors interested in penny stocks spread a lump sum across many biotech names. If this is a numbers game, diversification can be an effective strategy. With that in mind, here are two small-cap biotech stocks that carry significant risk but also offer the potential for outsized returns. Mainz Biomed: Early Cancer Detection With High Upside Potential Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular-diagnostics company focused on epigenetics-based tests for early cancer detection. Unlike many penny stocks in this space, Mainz Biomed already has a commercial product: ColoAlert — the first DNA-based screening tool for colorectal cancer in Europe. On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, a leading German digital-health pioneer. With more than 60,000 new colorectal cancer cases each year in Germany, the market opportunity is meaningful. Mainz Biomed is also developing a noninvasive blood-based screening test for early pancreatic cancer and reported positive topline results in October. That program, however, is still years from potential commercial approval. Still, risks are substantial. ColoAlert is not yet available in the United States, and despite early sales in Europe and plans to expand into South America, revenue remains minimal. To address liquidity concerns, the company included “Going Concern” language in its Sept. 26 SEC filing and has since filed a $150 million mixed-shelf offering. That capital should help keep MYNZ's share price above $1 and avoid a delisting notice for now. The company is racing to generate enough revenue to move the needle. If it succeeds, even a modest investment could yield a sizable return. NanoViricides: High-Risk Antiviral Play With Breakthrough Potential NanoViricides Inc. (NYSE: NNVC) is a micro-cap biotech pursuing a potentially disruptive antiviral approach — but it carries the financial risks investors should weigh carefully. The company is developing a novel class of antiviral therapies based on its proprietary "nanoviricide" platform. These drug candidates are designed to mimic human cell surfaces and lure viruses into binding with them, effectively neutralizing the pathogens before they can infect real cells. It's an innovative concept that, if validated in human trials, could represent a new method for treating infectious diseases. NanoViricides' pipeline includes candidates targeting shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced and has produced encouraging preclinical data suggesting strong antiviral activity. Like many micro-cap biotechs, NanoViricides remains pre-revenue and reliant on fresh capital to advance its programs. Recent filings indicated limited cash on hand, so investors should expect the possibility of future dilution. Still, if one candidate advances into clinical development successfully, the valuation upside could be substantial. For investors with patience and a high tolerance for risk, NNVC represents a genuine moonshot in the antiviral space.
| 
